INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $1,008,000 | -20.3% | 10,000 | 0.0% | 0.12% | -28.2% |
| Q3 2018 | $1,264,000 | +50.7% | 10,000 | 0.0% | 0.17% | +24.1% |
| Q2 2018 | $839,000 | +290.2% | 10,000 | +185.7% | 0.14% | +204.4% |
| Q1 2018 | $215,000 | +5.4% | 3,500 | 0.0% | 0.04% | -61.9% |
| Q4 2017 | $204,000 | -77.3% | 3,500 | -50.0% | 0.12% | -77.9% |
| Q1 2016 | $899,000 | -14.0% | 7,000 | 0.0% | 0.53% | -2.2% |
| Q4 2015 | $1,045,000 | -10.0% | 7,000 | 0.0% | 0.55% | -3.2% |
| Q3 2015 | $1,161,000 | -31.3% | 7,000 | 0.0% | 0.56% | -35.8% |
| Q2 2015 | $1,690,000 | -14.4% | 7,000 | 0.0% | 0.88% | -16.1% |
| Q1 2015 | $1,974,000 | -9.6% | 7,000 | -50.0% | 1.05% | +65.6% |
| Q4 2014 | $2,184,000 | – | 14,000 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |